Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03611010 · ClinicalTrials.gov registry record · Phase 2
Dose-ranging Efficacy and Pharmacokinetics Study of Intravenous Atorvastatin in Hypercholesterolemic Patients
A Phase 2 study, sponsored by Cumberland Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT03611010 is a Phase 2 study that has completed, run by Cumberland Pharmaceuticals. The registered enrollment target is 40 participants.
The verdict
NCT03611010, a Phase 2 study, has completed, sponsored by Cumberland Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
Open-label study will titrate doses of intravenous atorvastatin and monitor respective LDL-C levels in hypercholesterolemic patients previously controlled on oral atorvastatin.
Interventions
- DRUG Atorvastatin injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2018-08-07 |
| Est. Completion | 2020-02-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03611010
The ClinicalTrials.gov registry entry for NCT03611010 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cumberland Pharmaceuticals, which has 43 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Atorvastatin injection is the first listed.
NCT03611010 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03611010 about?
NCT03611010 is a clinical study titled "Dose-ranging Efficacy and Pharmacokinetics Study of Intravenous Atorvastatin in Hypercholesterolemic Patients". Open-label study will titrate doses of intravenous atorvastatin and monitor respective LDL-C levels in hypercholesterolemic patients previously controlled on oral atorvastatin.
What is the current status of trial NCT03611010?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2018-08-07. Estimated completion is 2020-02-24.
What interventions are being tested in trial NCT03611010?
The interventions under investigation include: Atorvastatin injection (DRUG).
Who is sponsoring clinical trial NCT03611010?
This trial is sponsored by Cumberland Pharmaceuticals, which has 43 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.